Answers are grounded in this paper and cite their sources.
Real-world evidence shows poor prognosis in metastatic nccRCC, with IO-TKI indicating potential benefits.
For metastatic nccRCC, unclassified RCC pathology and poor IMDC risk group were identified as independent risk factors for poor prognosis and IO-TKI showed promising efficacy in patients with metastatic nccRCC.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: